drugset / Trial / NCT00655122

Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study

NCT00655122

Phase 4 Terminated 8 enrolled Pfizer
RandomizedParallel-groupDouble-blindPrevention

Summary

The primary objective was to study the clinical benefit with dalteparin sodium in thromboprophylaxis in primary care medical subjects. The secondary objective was a pharmacoeconomic evaluation of hromboprophylaxis with dalteparin sodium in primary care medical subjects.

Timeline

Start
2003-04
Primary completion
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dalteparin sodium Other / unclassified 5000 iu Subcutaneous